Clinical DataExact Sciences' blood-based CRC screening test demonstrated 88.3% colorectal cancer sensitivity and 90.1% specificity, which is considered impressive.
Growth ProspectsA colon blood test will be an attractive additional revenue stream for EXAS, recognizing that Cologuard will remain the key to the company's long-term growth.
Product InnovationExact Sciences Corp's proprietary LBgard tubes yield 40% more DNA and have less variability than traditional test tubes.